Xywav

Xywav, bụ ọgwụ a na-eji agwọ cataplexy ma ọ bụ ụra ehihie gabigara ókè (EDS).^[1] O nwere nzube magburu onwe ha na kpo ngwakọta nke nnu oxybate, ya bụ Calcium oxybate. A na-aṅụ ya n'ọnụ.

N'ịbụ nke ụlọ ọrụ Jazz Pharmaceuticals mepụtara site na iji bịa na ímé ihe, a kwadoro ya maka iji ya mee ihe na United States na July 2020.^[2]^[3]

Ojiji ọgwụ

A na-egosi Xywav maka ọgwụgwọ nke cataplexy nke ụwa họrọ site na iji bịa na na ndị dị afọ asaa ma ọ bụ karịa na narcolepsy.

N'ọnwa Ọgọstụ 2021, U.S. Food and Drug Administration (FDA) kwadoro Xywav maka ọgwụgwọ nke idiopathic hypersomnia.

Mmetụta Ndị Ọzọ

Nsogbu iku ume

Ịdị nwayọ iku ume, Nsogbu iku ume, apnea ụra^[4]

Nsogbu Ahụ Ike Uche

Mgbagwoju anya, Hallucination, echiche ndị a na-adịghị ahụkebe ma ọ bụ ndị na-enye nsogbu (echiche na-adịghị mma), nchegbu, ịda mbà n'obi, echiche ma ọ bụ omume igbu onwe onye, ike ọgwụgwụ na-arịwanye elu, mmetụta nke obi amamikpe ma ọ bụ enweghị uru, Ihe isi ike ilekwasị anya^[4]

Ndị ọzọ

Ọha na omenala

Ọnọdụ iwu

U.S. Food and Drug Administration (FDA) nyere Xywav aha ọgwụ na-enweghị nne na nna na Nọvemba 1994.^[5] FDA nyere nkwado nke Xywav na Jazz Pharmaceuticals plc n'ọnwa Ọgọstụ 2021.^[6]

Aha ndị ọzọ

Ntụaka

↑ (13 November 2021) "Sleep-Wake Medications", Varcarolis' Manual of Psychiatric Nursing Care. Elsevier Health Sciences. ISBN 978-0-323-79306-3.
↑ Drug Approval Package: Xywav. U.S. Food and Drug Administration (FDA) (7 May 2021). Retrieved on 12 August 2021.
↑ Drug Approval Package: Xywav. U.S. Food and Drug Administration (FDA) (7 May 2021). Retrieved on 19 November 2021.
↑ ^4.0 ^4.1 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212690s000lbl.pdf
↑ Xywav Orphan Drug Designations and Approvals. U.S. Food and Drug Administration (FDA). Retrieved on 12 August 2021.
↑ Kpọpụta njehie: Invalid <ref> tag; no text was provided for refs named FDA PR 20210812

[1] (13 November 2021) "Sleep-Wake Medications", Varcarolis' Manual of Psychiatric Nursing Care. Elsevier Health Sciences. ISBN 978-0-323-79306-3.

[2] Drug Approval Package: Xywav. U.S. Food and Drug Administration (FDA) (7 May 2021). Retrieved on 12 August 2021.

[3] Drug Approval Package: Xywav. U.S. Food and Drug Administration (FDA) (7 May 2021). Retrieved on 19 November 2021.

[:03-4] 4.0 ^4.1 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212690s000lbl.pdf

[5] Xywav Orphan Drug Designations and Approvals. U.S. Food and Drug Administration (FDA). Retrieved on 12 August 2021.

[FDA_PR_20210812-6] Kpọpụta njehie: Invalid <ref> tag; no text was provided for refs named FDA PR 20210812

[1]

[2]

[3]

[4]

[5]

[6]